Mesothelioma

P2, N=65, Completed, University of Chicago | Active, not recruiting --> Completed

To our knowledge, this represents the first reported genetic profiling of MM with BM. The TP53 frameshift mutation is unusual for MM, and its potential association with rapid disease progression warrants further investigation. Given the aggressive nature of MM, SRS may be preferable to WBRT due to its shorter treatment time and ease of combination with systemic regimens.

P1/2, N=42, Not yet recruiting, AstraZeneca AB

P=N/A, N=19, Terminated, University Hospital, Toulouse | Completed --> Terminated; recruitment difficulties

P=N/A, N=32, Terminated, National Cancer Institute (NCI)

P2, N=140, Suspended, M.D. Anderson Cancer Center | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Dec 2026

P1/2, N=229, Recruiting, Orion Corporation, Orion Pharma

This case underscores the importance of considering MPM in the differential diagnosis of pleural effusion in young adults, even in the absence of asbestos exposure. Early pleural biopsy and immunohistochemical evaluation are essential to avoid diagnostic delay, particularly in tuberculosis-endemic settings.

Approaches include targeting viral transcripts directly (e.g., siRNAs against HBV surface antigen) or host factors critical for viral replication (e.g., anti-miR-122 miravirsen for HCV)...These include TargomiR (a miR-16 mimic for mesothelioma), cobomarsen (an anti-miR-155 for lymphomas), and MRX34 (a miR-34a mimic for various solid tumours)...Despite promising preclinical results, clinical translation has been hampered by issues like insufficient delivery efficiency to human tumours, toxicity, and the complex, interconnected regulatory networks of miRNAs, which can lead to unpredictable off-target effects. While RNA therapeutics hold immense promise, overcoming delivery barriers and enhancing understanding of RNA regulatory networks are essential for future success.

Our findings highlight that circulating miR-21 is a potential non-invasive biomarker with both diagnostic and independent prognostic value in pleural mesothelioma and outperforms SMRP in multivariable survival analysis. Further research is warranted to validate its role in the biology of this disease and to assess its correlation with outcome and treatment responses.

Altogether, these findings highlight exercise as a promising adjunct to immunotherapy for poorly immunogenic cancers such as pancreatic cancer and mesothelioma.

Collectively, our results indicate that BAP1 and USP1 appear to regulate FANCD2 through distinct, context-dependent mechanisms, with USP1 primarily influencing FANCD2 expression and BAP1 modulating FANCD2 function at the post-translational level. Together, these findings identify USP1 as a context-dependent therapeutic vulnerability in BAP1-deficient mesothelioma and support a working model in which USP1-dependent maintenance of FANCD2 function becomes critical in the absence of functional BAP1.